Alnylam Pharmaceuticals Inc (ALNY) — Financial Flexibility Index
Alnylam Pharmaceuticals Inc (ALNY) has a Financial Flexibility Index of 0.04x as of December 2025. Free cash flow of $186.85 Million (operating CF $163.56 Million minus capex $23.29 Million) represents 0% of total liabilities ($4.18 Billion). Check Alnylam Pharmaceuticals Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Alnylam Pharmaceuticals Inc Financial Flexibility Index (2002–2025)
Historical Financial Flexibility Index trend for Alnylam Pharmaceuticals Inc across 24 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Alnylam Pharmaceuticals Inc.
Annual Financial Flexibility Index for Alnylam Pharmaceuticals Inc (2002–2025)
Year-by-year free cash flow to debt coverage for Alnylam Pharmaceuticals Inc. Explore ALNY operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.14x | $582.78 Million | $524.08 Million | $4.18 Billion | ▲ +2142.2% |
| 2024 | 0.01x | $25.96 Million | $-8.31 Million | $4.17 Billion | ▼ -84.9% |
| 2023 | 0.04x | $166.37 Million | $104.16 Million | $4.05 Billion | ▲ +132.4% |
| 2022 | -0.13x | $-469.21 Million | $-541.27 Million | $3.70 Billion | ▲ +31.6% |
| 2021 | -0.19x | $-565.32 Million | $-641.69 Million | $3.06 Billion | ▲ +18.8% |
| 2020 | -0.23x | $-544.60 Million | $-614.96 Million | $2.39 Billion | ▼ -57.6% |
| 2019 | -0.14x | $-138.27 Million | $-278.43 Million | $956.44 Million | ▲ +90.9% |
| 2018 | -1.60x | $-435.73 Million | $-562.62 Million | $272.84 Million | ▼ -30.9% |
| 2017 | -1.22x | $-278.58 Million | $-382.79 Million | $228.30 Million | ▼ -71.9% |
| 2016 | -0.71x | $-243.14 Million | $-307.70 Million | $342.59 Million | ▲ +50.9% |
| 2015 | -1.45x | $-176.19 Million | $-189.14 Million | $121.80 Million | ▼ -32.3% |
| 2014 | -1.09x | $-156.68 Million | $-165.64 Million | $143.33 Million | ▼ -153.9% |
| 2013 | -0.43x | $-64.65 Million | $-68.66 Million | $150.18 Million | ▲ +38.4% |
| 2012 | -0.70x | $-107.26 Million | $-115.61 Million | $153.47 Million | ▼ -33.6% |
| 2011 | -0.52x | $-85.78 Million | $-87.07 Million | $163.92 Million | ▼ -54.5% |
| 2010 | -0.34x | $-79.61 Million | $-84.34 Million | $235.03 Million | ▼ -52.9% |
| 2009 | -0.22x | $-67.20 Million | $-72.14 Million | $303.42 Million | ▼ -202.4% |
| 2008 | 0.22x | $76.25 Million | $65.49 Million | $352.55 Million | ▼ -68.8% |
| 2007 | 0.69x | $204.31 Million | $196.52 Million | $294.62 Million | ▲ +237.1% |
| 2006 | -0.51x | $-19.64 Million | $-24.63 Million | $38.83 Million | ▼ -27.2% |
| 2005 | -0.40x | $-14.54 Million | $-16.48 Million | $36.57 Million | ▲ +24.9% |
| 2004 | -0.53x | $-10.56 Million | $-19.57 Million | $19.96 Million | ▼ -237.3% |
| 2003 | -0.16x | $-9.71 Million | $-12.83 Million | $61.89 Million | ▼ -354.8% |
| 2002 | -0.03x | $-716.00K | $-1.28 Million | $20.76 Million | — |